36 results on '"Ganesan, Shridar"'
Search Results
2. Reply to T. Ménard
3. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
4. Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing
5. Pooled analysis of POLE-mutant colorectal cancer characteristics.
6. Receptor-Defined Breast Cancer in Five East African Countries and Its Implications for Treatment: Systematic Review and Meta-Analysis
7. Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
8. Poly (ADP-Ribose) Polymerase Inhibitor Activity in Prostate Cancers Harboring Mutations in DNA Repair Genes: Who Benefits?
9. Molecular Profiling for Proper Diagnosis of Gastroenteropancreatic Neuroendocrine Tumor
10. Breast cancer receptor subtypes in East Africa: A systematic review and meta-analysis.
11. Detection of Three Distinct Clonal Populations Using Circulating Cell-Free DNA: A Cautionary Note on the Use of Liquid Biopsy
12. Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma Sharing the PCM1-JAK2 Fusion and a Common T-Cell Clone
13. Role for immune checkpoint blockade in BRCA2-mutant prostate cancer.
14. BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations
15. Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data
16. Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum
17. Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes.
18. Image-based risk score to predict recurrence of ER+ breast cancer in ECOG-ACRIN Cancer Research Group E2197.
19. Expression of endogenous retroviruses and response to immune checkpoint therapy in renal cell cancer.
20. Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors
21. Genomic alterations (GA) and tumor mutational burden (TMB) in large cell neuroendocrine carcinoma of lung (L-LCNEC) as compared to small cell lung carcinoma (SCLC) as assessed via comprehensive genomic profiling (CGP).
22. Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes.
23. Precision medicine for gallbladder cancer using somatic copy number amplifications (SCNA) and DNA repair pathway gene alterations.
24. Genomic profiling of squamous malignancies across anatomic sites.
25. Feasibility of collaborative precision medicine oncology between academic- and community-based hospitals.
26. Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.
27. Analysis of tumor mutation burden (TMB) in >51,000 clinical cancer patients to identify novel non-coding PMS2 promoter mutations associated with increased TMB.
28. Biomarkers for Immunotherapy: Current Developments and Challenges
29. Biomarkers for Immunotherapy: Current Developments and Challenges
30. A pilot study of neoadjuvant cetuximab in locally advanced squamous cell carcinomas of skin (SCCS).
31. Next-generation sequencing (NGS) as part of pathologic diagnostic armamentarium.
32. Therapeutic insights for malignant phyllodes from next-generation sequencing.
33. Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC).
34. Targeted treatment of RAI-resistant metastatic thyroid cancer postcomprehensive genomic profiling.
35. Randomized phase II trial of gemcitabine versus gemcitabine and imatinib mesylate in patients with previously treated metastatic breast cancer.
36. Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.